362 related articles for article (PubMed ID: 25171370)
1. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells.
Szabo A; Kovacs A; Frecska E; Rajnavolgyi E
PLoS One; 2014; 9(8):e106533. PubMed ID: 25171370
[TBL] [Abstract][Full Text] [Related]
2. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator.
Fontanilla D; Johannessen M; Hajipour AR; Cozzi NV; Jackson MB; Ruoho AE
Science; 2009 Feb; 323(5916):934-7. PubMed ID: 19213917
[TBL] [Abstract][Full Text] [Related]
3. IL-4 blocks TH1-polarizing/inflammatory cytokine gene expression during monocyte-derived dendritic cell differentiation through histone hypoacetylation.
López-Bravo M; Minguito de la Escalera M; Domínguez PM; González-Cintado L; del Fresno C; Martín P; Martínez del Hoyo G; Ardavín C
J Allergy Clin Immunol; 2013 Dec; 132(6):1409-19. PubMed ID: 24139608
[TBL] [Abstract][Full Text] [Related]
4. A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.
Frecska E; Szabo A; Winkelman MJ; Luna LE; McKenna DJ
J Neural Transm (Vienna); 2013 Sep; 120(9):1295-303. PubMed ID: 23619992
[TBL] [Abstract][Full Text] [Related]
5. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
[TBL] [Abstract][Full Text] [Related]
6. N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer's disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk.
Cheng D; Lei ZG; Chu K; Lam OJH; Chiang CY; Zhang ZJ
Alzheimers Res Ther; 2024 May; 16(1):95. PubMed ID: 38693554
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the innate immune responses of porcine monocyte-derived dendritic cells and splenic dendritic cells stimulated with LPS.
Qu X; Cinar MU; Fan H; Pröll M; Tesfaye D; Tholen E; Looft C; Hölker M; Schellander K; Uddin MJ
Innate Immun; 2015 Apr; 21(3):242-54. PubMed ID: 24648487
[TBL] [Abstract][Full Text] [Related]
8. Hallucinogens as discriminative stimuli: a comparison of 4-OMe DMT and 5-OMe DMT with their methythio counterparts.
Glennon RA; Young R; Benington F; Morin RD
Life Sci; 1982 Feb; 30(5):465-7. PubMed ID: 6801410
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 35: Inhibitory regulator in monocyte-derived dendritic cell maturation and activation.
Chen X; Hao S; Zhao Z; Liu J; Shao Q; Wang F; Sun D; He Y; Gao W; Mao H
Cytokine; 2018 Aug; 108():43-52. PubMed ID: 29571039
[TBL] [Abstract][Full Text] [Related]
10. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
Halberstadt AL
Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
[TBL] [Abstract][Full Text] [Related]
11. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor.
Su TP; Hayashi T; Vaupel DB
Sci Signal; 2009 Mar; 2(61):pe12. PubMed ID: 19278957
[TBL] [Abstract][Full Text] [Related]
12. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
[TBL] [Abstract][Full Text] [Related]
13. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Shen HW; Jiang XL; Winter JC; Yu AM
Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
[TBL] [Abstract][Full Text] [Related]
14. The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.
Tap SC
Addict Biol; 2024 Apr; 29(4):e13386. PubMed ID: 38600715
[TBL] [Abstract][Full Text] [Related]
15. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil extracellular traps downregulate lipopolysaccharide-induced activation of monocyte-derived dendritic cells.
Barrientos L; Bignon A; Gueguen C; de Chaisemartin L; Gorges R; Sandré C; Mascarell L; Balabanian K; Kerdine-Römer S; Pallardy M; Marin-Esteban V; Chollet-Martin S
J Immunol; 2014 Dec; 193(11):5689-98. PubMed ID: 25339673
[TBL] [Abstract][Full Text] [Related]
17. Opposite effects of N,N-dimethyltryptamine (DMT) and 5-methoxy-n,n-dimethyltryptamine (5-MeODMT) on acoustic startle: spinal vs brain sites of action.
Commissaris RL; Davis M
Neurosci Biobehav Rev; 1982; 6(4):515-20. PubMed ID: 6817240
[TBL] [Abstract][Full Text] [Related]
18. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
Winter JC; Filipink RA; Timineri D; Helsley SE; Rabin RA
Pharmacol Biochem Behav; 2000 Jan; 65(1):75-82. PubMed ID: 10638639
[TBL] [Abstract][Full Text] [Related]
19. Monocyte-derived dendritic cells from Crohn's disease patients exhibit decreased ability to activate T helper type 17 responses in memory cells.
Nieminen JK; Sipponen T; Färkkilä M; Vaarala O
Clin Exp Immunol; 2014 Jul; 177(1):190-202. PubMed ID: 24635023
[TBL] [Abstract][Full Text] [Related]
20. N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain.
Szabó Í; Varga VÉ; Dvorácskó S; Farkas AE; Körmöczi T; Berkecz R; Kecskés S; Menyhárt Á; Frank R; Hantosi D; Cozzi NV; Frecska E; Tömböly C; Krizbai IA; Bari F; Farkas E
Neuropharmacology; 2021 Jul; 192():108612. PubMed ID: 34023338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
